Literature DB >> 25071338

Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: old question new insights.

Carlos Sostres1, Carla Jerusalen Gargallo1, Angel Lanas1.   

Abstract

Previous reports clearly demonstrated that Helicobacter pylori (H. pylori) infection, nonsteroidal anti-inflammatory drugs (NSAID) or low dose aspirin (ASA) use significantly and independently increased the risk for the development of peptic ulcer disease. Today, the presence of H. pylori infection associated with low dose ASA and/or NSAID use in the same patient is becoming more frequent and therefore the potential interaction between these factors and the consequences of it has important implications. Whether NSAID intake in the presence of H. pylori infection may further increase the risk of peptic ulcer carried by the presence of only one risk factor is still a matter of debate. Studies on the interaction between the two risk factors yielded conflicting data and no consensus has been reached in the last years. In addition, the interaction between H. pylori infection and low-dose ASA remains even more controversial. In real clinical practice, we can find different clinical scenarios involving these three factors associated with the presence of different gastrointestinal and cardiovascular risk factors. These huge variety of possible combinations greatly hinder the decision making process of physicians.

Entities:  

Keywords:  Helicobacter pylori eradication; Helicobacter pylori infection; Low dose aspirin; Nonsteroidal anti-inflammatory drugs; Peptic ulcer disease

Mesh:

Substances:

Year:  2014        PMID: 25071338      PMCID: PMC4110575          DOI: 10.3748/wjg.v20.i28.9439

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  82 in total

1.  Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin.

Authors:  Stefano Fiorucci; Eleonora Distrutti; Octavio Menezes de Lima; Mario Romano; Andrea Mencarelli; Miriam Barbanti; Ernesto Palazzini; Antonio Morelli; John L Wallace
Journal:  FASEB J       Date:  2003-04-22       Impact factor: 5.191

2.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.

Authors:  Thomas J Schnitzer; Gerd R Burmester; Eduardo Mysler; Marc C Hochberg; Michael Doherty; Elena Ehrsam; Xavier Gitton; Gerhard Krammer; Bernhard Mellein; Patrice Matchaba; Alberto Gimona; Christopher J Hawkey
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

3.  Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration.

Authors:  C P Armstrong; A L Blower
Journal:  Gut       Date:  1987-05       Impact factor: 23.059

4.  Effect of Helicobacter pylori eradication on anti-thrombotic dose aspirin-induced gastroduodenal mucosal injury.

Authors:  Adnan Giral; Osman Ozdogan; Cigdem A Celikel; Nurdan Tozun; Nefise B Ulusoy; Cem Kalayci
Journal:  J Gastroenterol Hepatol       Date:  2004-07       Impact factor: 4.029

5.  Changing rates of Helicobacter pylori testing and treatment in patients with peptic ulcer disease.

Authors:  Mihnea V Chiorean; G Richard Locke; Alan R Zinsmeister; Cathy D Schleck; L Joseph Melton
Journal:  Am J Gastroenterol       Date:  2002-12       Impact factor: 10.864

6.  Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use.

Authors:  Carmen Martínez; Gerardo Blanco; José M Ladero; Elena García-Martín; Carlos Taxonera; Francisco G Gamito; Manuel Diaz-Rubio; José A G Agúndez
Journal:  Br J Pharmacol       Date:  2004-01-05       Impact factor: 8.739

7.  Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis.

Authors:  Loren Laine; Claire Bombardier; Christopher J Hawkey; Barry Davis; Deborah Shapiro; Christopher Brett; Alise Reicin
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

8.  Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH.

Authors:  A Morris; G Nicholson
Journal:  Am J Gastroenterol       Date:  1987-03       Impact factor: 10.864

9.  Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.

Authors:  Loren Laine; Eric S Maller; Chang Yu; Hui Quan; Thomas Simon
Journal:  Gastroenterology       Date:  2004-08       Impact factor: 22.682

10.  Gastritis increases resistance to aspirin-induced mucosal injury via COX-2-mediated lipoxin synthesis.

Authors:  Marcellus H L P Souza; Octavio Menezes de Lima; Stella R Zamuner; Stefano Fiorucci; John L Wallace
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2003-03-13       Impact factor: 4.052

View more
  10 in total

Review 1.  Helicobacter pylori virulence genes and host genetic polymorphisms as risk factors for peptic ulcer disease.

Authors:  Muhammad Miftahussurur; Yoshio Yamaoka
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-10-16       Impact factor: 3.869

Review 2.  Omega-3 polyunsaturated fatty acids as an angelus custos to rescue patients from NSAID-induced gastroduodenal damage.

Authors:  Jong Min Park; Young Min Han; Migyeong Jeong; Eun Hee Kim; Weon Jin Ko; Joo Young Cho; Ki Baik Hahm
Journal:  J Gastroenterol       Date:  2015-01-13       Impact factor: 7.527

Review 3.  Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy.

Authors:  Elham Patrad; Solmaz Khalighfard; Taghi Amiriani; Vahid Khori; Ali Mohammad Alizadeh
Journal:  Cell Oncol (Dordr)       Date:  2022-09-23       Impact factor: 7.051

Review 4.  Eicosanoid pathway in colorectal cancer: Recent updates.

Authors:  Sinem Tuncer; Sreeparna Banerjee
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

5.  Gastroprotective efficacy and safety evaluation of scoparone derivatives on experimentally induced gastric lesions in rodents.

Authors:  Dong Ju Son; Gyung Rak Lee; Sungil Oh; Sung Eun Lee; Won Sik Choi
Journal:  Nutrients       Date:  2015-03-13       Impact factor: 5.717

Review 6.  Fruit-Derived Polysaccharides and Terpenoids: Recent Update on the Gastroprotective Effects and Mechanisms.

Authors:  Mohammed Safwan Ali Khan; Syeda Umme Kulsoom Khundmiri; Syeda Rukhaiya Khundmiri; Mohammad M Al-Sanea; Pooi Ling Mok
Journal:  Front Pharmacol       Date:  2018-06-22       Impact factor: 5.810

Review 7.  International Consensus on Guiding Recommendations for Management of Patients with Nonsteroidal Antiinflammatory Drugs Induced Gastropathy-ICON-G.

Authors:  Richard Hunt; Leonid B Lazebnik; Yury C Marakhouski; Mircea Manuc; Ramesh Gn; Khin S Aye; Dmitry S Bordin; Natalia V Bakulina; Baurzhan S Iskakov; Abror A Khamraev; Yurii M Stepanov; Reidwaan Ally; Amit Garg
Journal:  Euroasian J Hepatogastroenterol       Date:  2019-02-01

8.  Risk of Recurrent Peptic Ulcer Disease in Patients Receiving Cumulative Defined Daily Dose of Nonsteroidal Anti-Inflammatory Drugs.

Authors:  Chih-Ming Liang; Shih-Cheng Yang; Cheng-Kun Wu; Yu-Chi Li; Wen-Shuo Yeh; Wei-Chen Tai; Chen-Hsiang Lee; Yao-Hsu Yang; Tzu-Hsien Tsai; Chien-Ning Hsu; Seng-Kee Chuah
Journal:  J Clin Med       Date:  2019-10-18       Impact factor: 4.241

9.  Clinical Risk Factors for Gastroduodenal Ulcer in Romanian Low-Dose Aspirin Consumers.

Authors:  Anca Negovan; Mihaela Iancu; Valeriu Moldovan; Septimiu Voidazan; Simona Bataga; Monica Pantea; Kinga Sarkany; Cristina Tatar; Simona Mocan; Claudia Banescu
Journal:  Gastroenterol Res Pract       Date:  2016-08-08       Impact factor: 2.260

10.  Helicobacter pylori in patients with gastritis in West Cameroon: prevalence and risk factors for infection.

Authors:  Nathan E Agbor; Seraphine N Esemu; Lucy M Ndip; Nicoline F Tanih; Stella I Smith; Roland N Ndip
Journal:  BMC Res Notes       Date:  2018-08-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.